No tumor progression was seen at three-year follow-up in Evaxion's melanoma vaccine trial.
Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All patients showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 showed a 75% objective response rate, with 25% of patients achieving complete response.
How this was made
The 30-second read
Why it matters
The three‑year durability data could trigger a re‑rating and partnership interest, potentially expanding the company's market cap.
Market read
First disclosure of durable three‑year efficacy for EVAX's melanoma vaccine, a material catalyst for the stock.
What to watch
Small trial size (12 patients) and lack of comparative data could limit price impact.
Background
Evaxion is a clinical‑stage TechBio company using AI‑Immunology™ to develop personalized cancer vaccines.
Ticker impact
Evaxion announced three-year phase‑2 melanoma vaccine data showing no tumor progression, indicating durable responses.
upward pressure as investors price in durable efficacy
Phase‑2 data with 100% disease control is material for a clinical‑stage biotech and can trigger a re‑rating.
Market effects
Strengthens the AI‑driven immunotherapy niche and may boost peer biotech valuations.
Positive for Copenhagen‑based biotech listings.
Adds confidence to personalized cancer vaccine approaches worldwide.
Counterpoint
If longer‑term safety or commercial path remains uncertain, the data may be over‑hyped.
Key entities
- companyEvaxion A/S
Clinical‑stage biotech developing personalized cancer vaccines.
- companyMerck & Co.
Provider of the anti‑PD‑1 therapy (Keytruda) used in the trial.
